News
MarketBeat on MSN1h
Sarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesIn another tragic incident, Sarepta Therapeutics (NASDAQ: SRPT) saw a second death in connection with its Duchenne muscular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback